Get the Stockscreener App
13.60
2.64%
0.35
After Hours:
13.57
-0.03
-0.22%
Benitec Biopharma Inc stock is traded at $13.60, with a volume of 175.90K.
It is up +2.64% in the last 24 hours and up +15.74% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$13.25
Open:
$13.16
24h Volume:
175.90K
Relative Volume:
1.16
Market Cap:
$467.22M
Revenue:
$7,000
Net Income/Loss:
$-38.96M
P/E Ratio:
-14.63
EPS:
-0.9296
Net Cash Flow:
$-18.34M
1W Performance:
+22.97%
1M Performance:
+15.74%
6M Performance:
-14.47%
1Y Performance:
-0.58%
1-Day Range:
$12.33
$13.97
1-Week Range:
$10.56
$13.97
52-Week Range:
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
13.60 | 455.19M | 7,000 | -38.96M | -18.34M | -0.9296 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Price-Driven Insight from (BNTC) for Rule-Based Strategy - Stock Traders Daily
Macro Review: How liquid is Benitec Biopharma Inc stock2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Quarterly Earnings: Does Benitec Biopharma Inc meet Warren Buffetts criteria2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Is Benitec Biopharma Inc part of any major index2026 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Entry Recap: What is the Moat Score of Benitec Biopharma IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
(BNTC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ideas Watch: How liquid is Benitec Biopharma Inc stockPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Sectors: Can Benitec Biopharma Inc maintain its current growth rate2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Market Wrap: Is Benitec Biopharma Inc stock a buy or sellQuarterly Market Summary & AI Enhanced Trading Alerts - baoquankhu1.vn
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving Average – Here’s What Happened - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(BNTC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Market Moves: Is Benitec Biopharma Inc forming a double bottom2026 Closing Moves & Verified Short-Term Plans - baoquankhu1.vn
BNTC SEC FilingsBenitec Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) FY 2025 loss widens to $37.9M - Stock Titan
Benitec Biopharma | 10-K/A: Annual report (Amendment) - Moomoo
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Risk Recap: What is the dividend yield of Benitec Biopharma Inc2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
Portfolio Recap: Is Benitec Biopharma Inc stock a good dividend stockDollar Strength & High Accuracy Swing Trade Signals - baoquankhu1.vn
Jerel A. Banks, MD, PhD, on Evaluating Gene Therapy BB-301 for OPMD-Related Dysphagia - CGTLive®
Surprises Report: Can Benitec Biopharma Inc maintain its current growth rate2026 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(BNTC) Risk Channels and Responsive Allocation - Stock Traders Daily
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for - The Manila Times
Benitec Biopharma to Host Industry Forum Breakfast Event at - GlobeNewswire
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
Cowen Reiterates Buy on Benitec Biopharma (BNTC) March 2026 - Meyka
Benitec Biopharma Inc. (BNTC) Competitors - Meyka
Benitec Biopharma : Corporate Presentation, March 2026 - marketscreener.com
Benitec BioPharma stock maintains Buy rating on positive trial data By Investing.com - Investing.com South Africa
Benitec BioPharma stock maintains Buy rating on positive trial data - Investing.com
BNTC: HC Wainwright & Co. Reiterates Buy Rating on Benitec Bioph - GuruFocus
Benitec reports interim results from gene therapy trial - Investing.com Nigeria
Benitec Biopharma (BNTC) Reports Encouraging Interim Results fro - GuruFocus
Benitec Biopharma Announces Positive Interim Phase 1b/2a - GlobeNewswire
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Bitget
Benitec Biopharma Stock Pre-Market (+7.1%): Analyst Raises EPS Forecasts - Trefis
Sentiment Recap: What is the Moat Score of Benitec Biopharma IncJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
New Highs: How liquid is Benitec Biopharma Inc stockJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
HC Wainwright Expects Higher Earnings for Benitec Biopharma - Defense World
HC Wainwright Issues Optimistic Forecast for BNTC Earnings - MarketBeat
Levels Update: Is Benitec Biopharma Inc exposed to political riskTreasury Yields & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Research Analysts Offer Predictions for BNTC Q1 Earnings - Defense World
Analysts Issue Forecasts for BNTC Q1 Earnings - MarketBeat
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Benitec Biopharma Inc. (BNTC) - DirectorsTalk Interviews
Benitec BioPharma stock rating maintained on gene therapy data - Investing.com Nigeria
Benitec BioPharma stock rating maintained on gene therapy data By Investing.com - Investing.com Australia
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):